Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cell 'secretome' may reboot the brain after stroke — a trial puts it to the test

NCT ID NCT07731087

Disease control Sponsor: Jumraini Tammasse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This pilot trial tests whether a substance made from stem cells — called mesenchymal stem cell secretome — can improve cognitive recovery in people who have had an ischemic stroke. Participants aged 40 to 75 with mild-to-moderate cognitive impairment will receive either standard stroke care alone or standard care plus two doses of the secretome. The study measures changes in thinking skills, brain wave patterns, and blood markers of brain health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
umbilical cord mesenchymal stem cell-derived secretome
What this could lead to
If it works, this could point toward a new add-on treatment to improve thinking and memory after a stroke.
What could go wrong
This is a small early pilot trial, so results may not be conclusive. The therapy carries risks of allergic reactions or fever, and its benefits for cognition are unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 40 to 75 years. 2. Diagnosis of ischemic stroke confirmed by clinical examination and computed tomography or magnetic resonance imaging. 3. Stroke onset between 7 days and 3 months before enrollment. 4. Hemodynamically stable. 5. Able to undergo a basic neuropsychological assessment. 6. Mild-to-moderate cognitive impairment based on the Indonesian version of the Montreal Cognitive Assessment. 7. Willing to participate in the study and provide written informed consent. Exclusion Criteria: 1. Hemorrhagic stroke or mixed ischemic and hemorrhagic stroke. 2. Severe aphasia, impaired consciousness, or severe sensory deficits that make cognitive assessment invalid. 3. History of dementia before stroke or a major neurodegenerative disorder. 4. Active infection, active autoimmune disease, active malignancy, severe renal failure, or severe liver failure. 5. Uncontrolled epilepsy. 6. Concurrent participation in another clinical trial. 7. Contraindication to any study intervention or study procedure.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke Post-stroke cognitive impairment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hasanuddin University Hospital

    RECRUITING

    Makassar, South Sulawesi, 90245, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.